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The nature of follicular helper CD4+ T (Tfh) cell
differentiation remains controversial, including the
minimal signals required for Tfh cell differentiation
and the time at which Tfh cell differentiation occurs.
Here we determine that Tfh cell development initiates
immediately during dendritic cell (DC) priming in vivo.
We demonstrate that inducible costimulator (ICOS)
provides a critical early signal to induce the transcrip-
tion factor Bcl6, and Bcl6 then induces CXCR5, the
canonical feature of Tfh cells. Strikingly, a bifurcation
between Tfh and effector Th cells wasmeasurable by
the second cell division of CD4+ T cells, at day 2 after
an acute viral infection: IL2Raint cells expressed Bcl6
and CXCR5 (Tfh cell program), whereas IL2Rahi cells
exhibited strong Blimp1 expression that repressed
Bcl6 (effector Th cell program). Virtually complete
polarization between Bcl6+ Tfh cells and Blimp1+
effector Th cell populations developed by 72 hr,
even without B cells. Tfh cells were subsequently
lost in the absence of B cells, demonstrating a B
cell requirement for maintenance of Bcl6 and Tfh
cell commitment via sequential ICOS signals.
INTRODUCTION
Naive CD4+ T cells differentiate into different effector cells and
elicit various immunological effector functions, such as clearing
viruses (Th1 cells), helminths (Th2 cells), and fungi (Th17 cells)
or suppressing immune responses (iTreg cells) (Zhu et al.,
2010). Follicular helper T (Tfh) cells are the CD4+ T cells special-
ized in B cell help (Crotty, 2011). Tfh cells express the B cell
homing chemokine receptor, CXCR5, among other molecules
important for their differentiation and function. CXCR5 surface
expression not only phenotypically distinguishes Tfh cells from
other effector CD4+ T cells but functionally drives Tfh cell
migration into B cell follicles in a CXCL13-dependent manner.
T cell help to B cells is a pivotal process of adaptive immune
responses. Tfh cells first interact with cognate B cells at the
T cell-B cell border and subsequently induce germinal center B932 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.cell differentiation and germinal center formation within the
follicle (Allen et al., 2007). Tfh cells have a gene expression profile
that is distinct from Th1, Th2, Th17, and iTreg cells (Chtanova
et al., 2004; Nurieva et al., 2008; Rasheed et al., 2006; Vinuesa
et al., 2005; Yusuf et al., 2010) and is particularly enriched for
cell surface molecules, reflecting the importance of cell-cell
interactions between Tfh cells and B cells for Tfh cell functions.
The Tfh cell program in both mice and humans is associated
with high expression of CXCR5, PD-1, ICOS, BTLA, IL-21,
SAP, and Bcl6 (Crotty, 2011).
Effector CD4+ T cell differentiation is controlled by specific
transcription factors (Murphy and Stockinger, 2010; Zhu et al.,
2010). We and others recently identified a transcriptional
repressor, Bcl6, as a critical regulator of Tfh cell differentiation
(Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009).
Bcl6 is a BTB domain containing transcriptional repressor previ-
ously known to be required in B cells for germinal center B cell
differentiation, and Bcl6 is an important oncogene in germinal
center B cell-derived lymphomas (Ci et al., 2008; Klein and
Dalla-Favera, 2008). Bcl6-deficient CD4+ T cells are not able to
differentiate into Tfh cells in vivo (Johnston et al., 2009; Nurieva
et al., 2009; Yu et al., 2009), whereas constitutive Bcl6 expres-
sion induced CD4+ T cell differentiation into Tfh cells (Johnston
et al., 2009). These results demonstrated that not only is Bcl6
expression required in B cells for germinal center development,
it is also simultaneously essential in CD4+ T cells, and thus Bcl6
must regulate complementary gene expression programs in two
different lymphocyte cell types differentiating in parallel. One of
the functions of Bcl6 in Tfh cell differentiation is to regulate
miRNA expression. Bcl6 downregulated miRNA clusters that
were shown to partially inhibit CXCR5 in B cells (Yu et al.,
2009). Bcl6 can repress expression or function of transcription
factors necessary for other CD4+ T cell differentiation pathways,
such as RORgt (Nurieva et al., 2009). Bcl6 also directly represses
the transcription factor Blimp1 (encoded by Prdm1) (Johnston
et al., 2009; Tunyaplin et al., 2004). All of these data demonstrate
that Bcl6 is necessary and sufficient for Tfh cell differentiation by
CD4+ T cells. Therefore, a deeper understanding of the regula-
tion of Bcl6 expression is essential to understand Tfh cell
differentiation.
Different models have been proposed to explain Tfh cell differ-
entiation, which hinge on different Bcl6 expression kinetics and
mechanisms of induction. One model proposed is cytokine-
dependent Tfh cell differentiation. Th1 and Th2 CD4+ T cell
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T cells with activation signals through the TCR and appropriate
cytokine receptors (Zhu et al., 2010). Analogously, it was
proposed that Tfh cells can be differentiated in vitro by IL-6 or
IL-21. Both Bcl6 mRNA and CXCR5 mRNA were upregulated
in the presence of IL-6 or IL-21 (Nurieva et al., 2008, 2009).
However, this simple model has been challenged by studies
that found normal Tfh cell differentiation in vivo in the absence
of IL-6 or IL-21 (Poholek et al., 2010; Zotos et al., 2010), though
partial defects were found in other studies (Linterman et al.,
2010; Vogelzang et al., 2008), possibly because of reduced
maintenance of Tfh cells (Linterman et al., 2010). There have
been conflicting reports regarding cytokine induction of Bcl6
and CXCR5 in vitro (Dienz et al., 2009; Eddahri et al., 2009). In
our studies, limited Bcl6 and CXCR5 mRNA was induced by
in vitro purified CD4+ T cells cultured in the presence of TCR
stimulation plus IL-6 or IL-21, and no substantial expression of
Bcl6 protein or CXCR5 protein was found (Eto et al., 2011). Cyto-
kines alone appear to be insufficient for Tfh cell differentiation.
Other models have focused on the importance of B cell-
dependent Tfh cell differentiation (Crotty et al., 2010). This model
is supported by the observation that Tfh cell differentiation was
severely defective in B cell-deficient mice (mMT) or cognate B
cell-deficient mice (MD4-mMT) after protein immunization, viral
infection, or parasite infection (Haynes et al., 2007; Johnston
et al., 2009; Zaretsky et al., 2009). B cell-dependent Bcl6 induc-
tion for Tfh cell differentiation was further evidenced by rescuing
Tfh cell differentiation in mMT mice by constitutive expression of
Bcl6 in antigen-specific CD4+ T cells (Johnston et al., 2009). B
cell-dependent Tfh cell differentiation is, however, challenged
by a recent study that found Tfh cells could develop in mice defi-
cient for MHCII only on B cells if mice were given repeated Ag
injection (Deenick et al., 2010). The interdependence of Tfh cell
and GC B cell differentiation, both of which require Bcl6, adds
an additional layer of complexity to assessing the cell autonomy
of Tfh cell defects.
An alternative model has proposed that Tfh cell differentiation
is not an independent developmental pathway, but instead Tfh
cells are possibly a subsequent state of Th1, Th2, and Th17 cells
(Awasthi and Kuchroo, 2009; Bauquet et al., 2009; Murphy and
Stockinger, 2010; Zaretsky et al., 2009). Several studies have
shown that Tfh cells can exhibit features of Th1, Th2, and Th17
cells (Bauquet et al., 2009; Fazilleau et al., 2009; Johnston
et al., 2009; Reinhardt et al., 2009; Zaretsky et al., 2009). Indeed,
such cytokine production is important for appropriate induction
of B cell class switch recombination. Nevertheless, Bcl6 is
capable of repressing Th1, Th2, and Th17 cell programs (Nurieva
et al., 2009), and Tfh cells generally express low amounts of Th1,
Th2, or Th17 cell-associated cytokines and transcription factors,
particularly in humans (Breitfeld et al., 2000).
Given that Bcl6 is a critical regulator for Tfh cell differentiation,
it is crucial to understand the regulation of Bcl6 induction in CD4+
T cells. Therefore, in this study, we probed the differentiation of
CD4+ T cells in vivo to determine molecular and cellular cues
for Bcl6 expression and the kinetics of Tfh cell differentiation.
We demonstrate that Tfh cell differentiation occurs early after
viral infection, as an independent differentiation program that is
dependent on ICOS signals during DC priming, independent of
B cells. We further show that an APC transition then occursfrom DCs to B cells and ICOS signaling is again required
a second time for maintenance of Bcl6 and Tfh cells. These
results allow for the development of an integrated model of Tfh
cell differentiation.
RESULTS
Early Development of Bcl6+CXCR5+ Tfh Cells In Vivo
Tfh cells are readily identifiable at the peak of the CD4+ T cell
response to an acute LCMV infection as CXCR5hiSLAMlo
BTLAhiPD1hiBcl6+ virus-specific CD4+ T cells. Equivalent results
are observedwith either LCMVgp-specific TCR transgenic CD4+
T cells (SMARTA or SM) (Figure 1A) or polyclonal CD4+ T cells
(Figure S1 available online). Tfh (CXCR5+) antiviral CD4+ T cells
at the peak of the immune response express Bcl6 (p = 0.0002)
(Figure 1B).
To probe the molecular and cellular requirements of Tfh cell
differentiation, we examined the kinetics of Tfh cell development
in vivo, with a particular focus on when Bcl6 protein expression
was induced, because Bcl6 is required for Tfh cell differentiation
and expression of Bcl6 is sufficient to induce Tfh cell differentia-
tion. SMCD4+ T cells were transferred into B6mice and analyzed
3 and 4 days after LCMV infection. Strikingly, robust numbers of
Bcl6+CXCR5+CD4+ T cells were present at day 3 (Figure 1C).
Surface CXCR5 expression was induced 15- to 30-fold higher
on Bcl6+ cells than naive CD4+ T cells (p = 0.0001, day 3;
p = 0.0005, day 4; Figure 1D). Tfh cells are Bcl6+CXCR5+CD4+
T cells. Because PD-1 is a third canonical Tfh cell marker (Chta-
nova et al., 2004; Haynes et al., 2007; Linterman et al., 2009), we
examined PD-1 expression. Day 3 Bcl6+CXCR5+ SM expressed
highly elevated PD-1 compared to the CXCR5 SM population
(CXCR5+ versus CXCR5 PD-1 MFI, p = 4.0 3 105; Figures
1E and 1G). Tfh cell differentiation was further evidenced by anal-
ysis of ICOS expression, which is highly expressed on Tfh cells in
humans and mice (Breitfeld et al., 2000; Vinuesa et al., 2005).
Indeed, day 3 CXCR5+ SM expressed significantly more ICOS
(p = 0.0005 versus CXCR5 SM; Figure S1D). Interestingly, early
Tfh cells also expressed more CD69 than effector Th antiviral
CD4+ T cells (CXCR5+ versus CXCR5 CD69 MFI, p = 0.0001;
Figures 1F and 1H). CD69 inhibits S1P1-dependent egress of
T cells from lymphoid tissues (Pham et al., 2008) and probably
enhances retention of Tfh cells in and near B cell follicles (Fazil-
leau et al., 2007). Taken together, our Bcl6 data indicated that the
Tfh cell developmental program commences early during CD4+
T cell priming in vivo.
DCPriming: SAP, CD40, andBCell-Independent TfhCell
Commitment
Tfh cells are crucial for the development of germinal centers,
from which long-lived plasma cells and memory B cells are
predominantly generated (Allen et al., 2007; Good-Jacobson
et al., 2010). Germinal center formation requires SLAM-associ-
ated protein (SAP, encoded by Sh2d1a) expression in CD4+
T cells (Crotty et al., 2003; Qi et al., 2008). SAP is an intracellular
signaling molecule that binds to members of the SLAM family of
receptors, which are prominently expressed on T and B cells
(Cannons et al., 2011). SAP deficiency in CD4+ T cells severely
impairs the duration of cognate interactions with B cells,
whereas the absence of SAP does not affect CD4+ T cell-DCImmunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc. 933
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Figure 1. Bcl6+CXCR5+ Tfh Cell Differentiation Occurs within 72 hr In Vivo
(A–D) LCMV-specific SM CD4+ T cells were transferred into B6 mice that were subsequently infected with LCMV.
(A) Bcl6+CXCR5+ Tfh cells analyzed 7 days postinfection (p.i.) (‘‘d7’’) versus naive (‘‘N,’’ CD44loCD62hi) CD4+ T cells of uninfected control mice.
(B) Bcl6 protein expression in day 7 SM as D MFI (e.g., Bcl6 MFITfh  Bcl6 MFInaive CD4).
(C) Bcl6+CXCR5+ Tfh cells, 3 and 4 days p.i. (‘‘d3,’’ ‘‘d4’’). ‘‘N,’’ uninfected mice. FACS plot shows SM CD4+ T cells.
(D) Increase in SM CXCR5 MFI compared to that of naive (CD44loCD62hi) CD4+ T cells of uninfected mice.
(E–H) Day 3 and 4 after LCMV infection, PD-1 (E) and CD69 (F) coexpression with CXCR5 on SM CD4+ T cells.
(G and H) PD-1 (G) and CD69 (H) MFIs of CXCR5+ SM versus CXCR5 SM.
Data are representative of three or more independent experiments; n = 4 per time point for all panels. ***p < 0.001. Error bars are SEM. See also Figure S1.
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Tfh Cell Fate Determination Pathwaysinteractions (Cannons et al., 2010; Qi et al., 2008). We therefore
examined whether SAP has a role in early Tfh cell differentiation
in vivo.Sh2d1a/SMCD4+ T cells were transferred into C57BL/
6 mice (B6) and analyzed for Tfh cell differentiation after acute
LCMV infection. Both CXCR5 induction and Bcl6+CXCR5+ Tfh
cell development (Figure 2A) by Sh2d1a/ SM CD4+ T cells
were normal at day 3 and day 4 in vivo. Thus, Bcl6 expression
and Tfh cell differentiation is induced in CD4+ T cells prior to sus-
tained B cell-T cell interactions.
CD40 is also required for germinal center development
(MacLennan, 1994) and is prominently expressed on B cells.
Therefore we analyzed whether CD40L signals direct early Tfh934 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.cell development. We tested the early Tfh cell commitment of
SM CD4+ T cells in Cd40/ mice. Robust Bcl6 induction was
observed in the absence of CD40, and the frequency of
Bcl6+CXCR5+ CD4+ T cells was normal (Figure 2B). However,
lack of CD40 results in a severe truncation of the B cell response
byday8 (FigureS2A)and resulted ina lossofTfhcells (FigureS2B).
The finding of early Bcl6 induction revealed a conundrum,
because Tfh cells were previously demonstrated to require the
presence of cognate B cells in the work of our lab (Johnston
et al., 2009) and others (Haynes et al., 2007; Zaretsky et al.,
2009). We have confirmed those earlier results (WT versus
mMT Tfh cells = 50% versus 18%; p = 1.8 3 105; Figure 2C)
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Figure 2. Early Bcl6+CXCR5+ Tfh Cell Differentiation Is B Cell Independent and Does Not Require SAP- or CD40L-Mediated Signals
(A) Naive Sh2d1a/ or WT SM CD4+ T cells were transferred into B6 mice subsequently infected with LCMV. Bcl6+CXCR5+ Tfh cell differentiation analyzed at
3 and 4 days p.i. FACS plots show Sh2d1a/ SM and gates identify Bcl6+CXCR5+ Tfh cells.
(B) WT SM CD4+ T cells were transferred into either B6 or Cd40/mice subsequently infected with LCMV. Tfh cell differentiation was analyzed as shown in (A).
(C andD) SMCD4+ T cells were transferred into B6 or B cell-deficient (mMT)mice and infectedwith LCMV, and the CD4+ T cell responsewas analyzed 7 days later.
(C) SM CD4+ T cells are shown. Gate indicates SLAMloCXCR5hi Tfh cells.
(D) SM cells are shown and gates identify Bcl6+CXCR5+ Tfh cells. Bcl6 protein calculated D MFI (e.g., Bcl6 MFITfh  Bcl6 MFInaive CD4).
(E and H) SMCD4+ T cells were transferred into B6 and mMT (or MD4-mMT. B def.) mice. Mice were then infected with LCMV and analyzed 3 (E) and 4 (H) days p.i.
FACS plots show total SM cells, and gates identify Bcl6+CXCR5+ Tfh cells. Data are a composite of three or more independent experiments (n = 15–16 per group
for day 3, n = 17–20 per group for day 4).
(F and G) LCMV Gp61 peptide-pulsed DCs were activated in vitro with LPS and transferred into B6 mice that had received naive SM CD4+ T cells. SM were
analyzed 4 days after DC immunization.
(F) Left, SM CD4+ T cells in DC-immunized (red line) versus unimmunized mice (gray filled) compared to that of endogenous naive (CD44lo) CD4+ T cells in
DC-immunized mice (black line). Right, CXCR5 MFIs calculated. Day 4 SM (‘‘day 4’’) versus SM in unimmunized mice (‘‘N’’).
(G) Bcl6+CXCR5+ Tfh cells.
(A–D, F, and G) Data are representative of two independent experiments. n = 4 per group.
n.s., no statistically significant difference (p > 0.05). *p < 0.05, ***p < 0.001. Error bars are SEM. See also Figure S2.
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severely reduced at the peak of the antiviral CD4+ T cell response
in the absence of B cells (p = 0.014; Figure 2D). This led us to
directly examine whether B cells were required for early Tfh
cell differentiation. Clear Bcl6 induction and Bcl6+CXCR5+ Tfh
cell differentiation was present in the absence of total (mMT) or
cognate B cells (MD4-mMT) at day 3 in vivo (B def.; Figure 2E).
Thus, early Tfh cell differentiation is B cell independent.Given that Tfh cell differentiation initiates early and is B cell
independent, DCs were implicated. To determine whether DCs
could directly induce Tfh cell differentiation, we conducted
in vivo experiments with peptide-pulsed DCs. Indeed, DC immu-
nization was sufficient to induce CXCR5 expression (p = 3.2 3
105; Figure 2F) and Bcl6 expression (p = 0.0001; Figure 2G)
by CD4+ T cells. This was not due to transfer of antigen from
DCs to B cells; comparable CXCR5 induction was observed inImmunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc. 935
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Tfh Cell Fate Determination PathwaysDC-immunized H2/ recipients (Figures S2C and S2D). These
results strongly indicated that DC priming is sufficient to induce
Bcl6 expression and initial Tfh cell differentiation.
B cell-independent Tfh cell differentiation led us to analyze
whether Tfh cells require sequential antigen presentation by
DCs and B cells, with early Tfh cell commitment being instructed
by DCs and Tfh cell maintenance determined by B cells.
Whereas normal Bcl6+CXCR5+ Tfh cell differentiation was
present in the absence of cognate B cells (mMT or
MD4-mMT mice) at day 3 p.i. (Figure 2E), the frequency of
Bcl6+CXCR5+CD4+ T cells was significantly reduced at day 4
(p = 1.79 3 109; Figure 2H), which implied that a major APC
transition from DCs to B cells occurs for CD4+ T cells approxi-
mately 3 to 4 days after an acute infection. This is consistent
with a recent report that Tfh cells were present in the absence
of B cells when mice were given continuous antigen via peptide
injection (Deenick et al., 2010). Our data thus far indicate that
early induction of Bcl6 and Tfh cell development occurs during
interaction with DCs and is independent of SAP- or CD40-medi-
ated signals, whereas maintenance of Bcl6 expression and
stable commitment to Tfh cell differentiation normally requires
additional interactions with cognate B cells.
ICOS Instructs Tfh Cell Differentiation
These observations led us to explore DC signals that could
initiate Bcl6 induction and instruct Tfh cell differentiation. Interest
in early signals controlling Tfh cell differentiation led us to
examine ICOS signaling. Reduced numbers of Tfh cells are
observed in the absence of ICOS signals (Akiba et al., 2005;
Gigoux et al., 2009). However, it has not been addressedwhether
ICOS-mediated signals are required for Bcl6 induction and initi-
ation of Tfh cell differentiation. To determine this, we analyzed
whether Icos/ SM CD4+ T cells undergo early Tfh cell differen-
tiation in vivo. Strikingly, Bcl6 induction was severely reduced in
the absence of ICOS (p = 7.8 3 105 at day 3, p = 0.00093 at
day 4; Figures 3A–3C). CD4+ T cell activation and proliferation
were not affected by the absence of ICOS (Figures S3A–S3D).
Icos/ SM failed to differentiate to Tfh cells, with near-back-
groundTfh cell frequencies at day 3 (p =0.0001; Figure 3D). Bcl6hi
Icos/ SM CD4+ T cells were absent (Figure S3F). At day 4,
a similarly severe loss of Icos/ Tfh cells was seen (p = 4.65 3
106; Figure 3D). The rare Icos/ Tfh cells remaining had aber-
rantly low levels of Bcl6 (p = 3.95 3 107; Figure 3C) and
CXCR5 (p = 7.4 3 107; Figure 3E and Figure S3E). Thus,
ICOS-mediated signals are crucial for Bcl6 induction during
CD4+ T cell priming for initiation of Tfh cell differentiation.
Sequential ICOS Requirements for Tfh Cells
and Germinal Centers
Given the early Tfh cell defect of Icos/ CD4+ T cells, we then
analyzed the impact of the Tfh cell defect on the magnitude of
the germinal center B cell response in Icos/mice after an acute
VACV infection. Germinal centers were impaired at day 8 in
Icos/ mice compared to WT controls (p = 0.0004; Figure 4A).
This was consistentwith severe germinal center defects reported
in ICOS-deficient mice in response to nonreplicating antigens
(Akiba et al., 2005; McAdam et al., 2001; Tafuri et al., 2001).
CD4+ T cell activation was normal (CD44hiCD62LloCD4+ T cell
frequency; 24.0% ± 2.3% WT versus 26.3% ± 7.3% ICOS/).936 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.The defective germinal centers after VACV infection were prob-
ably a direct consequence of the reduced availability of T cell
help, as indicated by the fact that Tfh cell numbers were signifi-
cantly reduced in Icos/ mice at day 8 after VACV infection
(p = 0.002; Figure 4B). Remaining Icos/ Tfh cells had signifi-
cantly reduced CXCR5 expression (p = 0.0015; Figure 4B). Two
populations of Tfh cells can be distinguished phenotypically
in vivo (Haynes et al., 2007; Yusuf et al., 2010). Tfh cells physically
within germinal centers (GC Tfh cells) have the highest PD-1
expression (Haynes et al., 2007) and can be distinguished on
the basis of GL7 expression in mice with an acute viral infection
(Yusuf et al., 2010). Generation of GC Tfh cells was impaired in
the absence of ICOS-mediated signals in mice 8 days postinfec-
tion (p = 0.042; Figure 4C). Defective Tfh cell differentiation and
CXCR5 induction werewell correlated with a loss of Bcl6 expres-
sion by the Icos/ CD4+ T cells (p = 0.0004; Figure 4D). Icos/
Tfh cell and GC Tfh cell defects were evenmore severe by day 12
after VACV infection (Figures 4E–4G). Icos/ Tfh cell frequen-
cies were merely 27% of normal (p = 4.2 3 106; Figure 4E),
and Icos/GC Tfh cells were barely detectable (p = 0.0001; Fig-
ure 4F). As a result, Icos/ germinal centers decayed rapidly,
with a 95% loss of GC B cells at day 12 after VACV infection
(p = 0.0005; Figure 4G and Figure S4A). Similar defects were
found after LCMV infection of Icos/ mice (Figures S4B–S4D).
Experiments above show a requirement for ICOS early during
DC priming. DCs and B cells both express ICOSL, the ligand for
ICOS. Icosl/ mice were unable to support Tfh cell differentia-
tion, as shown by the fact that wild-type SM cells transferred
into Icosl/ recipients failed to develop a Bcl6hi population
(data not shown). A major APC transition from DCs to B cells
occurs at 3–4 days p.i. (Figure 2). Therefore, we explored
whether ICOSL signals were required both early and late during
Tfh cell differentiation. ICOS signals after CD4+ cells priming
were blocked by in vivo treatment with anti-ICOSL (aICOSL)
starting at day 3 p.i. (Figure S4E). ICOSL blockade after priming
resulted in a significant loss of Tfh cells (25%, p = 0.0004; Fig-
ure 4H) andGCTfh cells (50%, p = 0.003; Figure 4I) by day 8 p.i.
Importantly, Bcl6-expressing CD4+ T cells were substantially
reduced (p = 0.0001; Figure 4J). Germinal centers were severely
reduced (p = 0.005; Figure 4K), whereas overall B cells and acti-
vated CD4+ T cell numbers were largely unaffected (data not
shown). Taken together, these data demonstrate that there
are two independent Tfh cell requirements for ICOS during
sequential interactions with different APCs. ICOSL is first
required on DCs for Tfh cell induction and ICOSL is then required
again during T cell-B cell interactions for maintenance of Bcl6
expression.
ICOS Induction of Bcl6 Leads to Bcl6 Induction
of CXCR5
Overall, the experiments elaborated above showed that Tfh cell
development is present by day 3 in vivo and ICOS-mediated
signals are essential. However, it was not known why ICOS is
required. Is the signaling hierarchy such that ICOS induces Bcl6
first and then Bcl6 induces CXCR5, or is Bcl6 induction depen-
dent on CXCR5 expression? Or does ICOS directly induce both
CXCR5 and Bcl6 independently? To address these questions,
we determined whether ICOS could induce CXCR5 expression
on CD4+ T cells in the absence of Bcl6. Bcl6 expression in SM
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Figure 3. Early Tfh Cell Commitment Requires ICOS Signals for Bcl6 Expression
WT or Icos/ SM CD4+ T cells were transferred into B6 mice subsequently infected with LCMV.
(A and B) Bcl6+CXCR5+ Tfh cell development was analyzed 3 and 4 days p.i. by FACS (A) and quantified (B).
(C) Bcl6 protein expression was quantified in WT CXCR5+ SM and WT CXCR5 SM versus Icos/ SM CD4+ T cells.
(D) PD-1 expression on WT and Icos/ SM CD4+ T cells.
(E) Left, CXCR5 expression on WT (black) and Icos/ (red) SM CD4+ T cells, compared to isotype control (gray filled). Right, CXCR5 MFIs.
Data are representative of three independent experiments; n = 4 per group. ***p < 0.001. Error bars are SEM. See also Figure S3.
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Tfh Cell Fate Determination PathwaysCD4+ T cells was prevented by expression of Blimp1 (Prdm1-RV;
Figure S5A). Mice received a 1:1 mixture of control and Prdm1-
RV+ SM cells (Figure 5A). Although SM CD4+ T cell activation
(CD44hi; Figure S5D) and proliferation (Figure 5B) was normal at
day 4 after LCMV infection, Bcl6 expression was efficiently
blocked (p=4.793105 at day3; FigureS5CandFigure5E, right;
p = 0.0008 at day 4; Figures 5C and 5D, right). Importantly, CD4+T cells were unable to upregulate CXCR5 expression in the
absence of Bcl6 (p = 6.0 3 105 at day 3; Figure S5B and Fig-
ure 5E, left; p = 0.0008 at day 4; Figures 5C and 5D, left).
In another set of experiments, Bcl6 expression was directly
quenched in SM CD4+ T cells by expressing Bcl6 shRNA in the
context of a natural micro RNA backbone for optimal processing
(shRNAmir). Whereas both expansion (Figure 5F) and activationImmunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc. 937
Day 8
Fa
s
WT Icos-/-
WT Icos-/-
PNA
SL
AM
WT Icos-/-
CXCR5
Tfh Day 8
B
WT Icos-/-
Tf
h 
%
WT Icos-/-
CX
CR
5 
M
FI
A
D
CXCR5
Bc
l6
WT Icos-/-
Day 8
Bc
l6
+
CX
CR
5+
WT Icos-/-
C
G
L-
7
CXCR5
GC Tfh Day 8
WT Icos-/-
G
C 
Tf
h 
%
G
C 
B 
%
WT Icos-/-
E
CXCR5
SL
AM
G
L-
7
CXCR5
Tfh Day 12
WT Icos-/- WT Icos-/-
F
GC Tfh Day 12
G
WT Icos-/- WT Icos-/-
Tf
h 
%
CX
CR
5 
M
FI
WT Icos-/-
G
C 
Tf
h 
%
WT Icos-/-
G
C 
B 
%
K
Fa
s
PNA
Ctrl mAb αICOSL
C αICOSL N
G
C 
B 
%
H
SL
AM
CXCR5
Ctrl mAb αICOSL
Tf
h 
%
C αICOSL
I
G
L7
CXCR5
αICOSLCtrl mAb
G
C 
Tf
h 
%
C αICOSL
Bc
l6
CXCR5
J
Ctrl mAb αICOSL
Bc
l6
+
CX
CR
5+
 
%
C αICOSL
CX
CR
5 
M
FI
C αICOSL
***
** **
****
*** *** *** ***
***
***
**
*** ***
Figure 4. ICOS-Dependent Tfh Cell Maintenance and Germinal Center Formation
B6 and Icos–/– mice were infected with vaccinia virus (VACV). Mice were analyzed 8 days p.i. (A–D) and 12 days p.i. (E–G).
(A) Representative FACS plots of germinal center B cells (Fas+PNA+). Total B220+ B cells are shown. Right, GC B cells were quantified as percent of total B cells.
(B) Representative FACS plots of WT and Icos/ polyclonal Tfh cells. Activated CD4+ T cells (CD44hiCD62Llo) are shown and gates identify SLAMloCXCR5+ Tfh
cells. Tfh cell frequencies (percent of activated CD4+ T cells [CD44hiCD62Llo]) and CXCR5 MFIs were quantified.
(C) Representative FACS plots of WT and Icos/ polyclonal GC Tfh cells. Activated CD4+ T cells (CD44hiCD62Llo) are shown and gates identify GL7+CXCR5hi GC
Tfh cells. GC Tfh cell frequencies were quantified (percent of activated CD4+ T cells [CD44hiCD62Llo]).
(D) Representative FACS plots of Bcl6 expression by CD4+ T cells in B6 and Icos/ mice. Bcl6+CXCR5+ Tfh cells were quantified (percent of activated CD4+
T cells).
(E–G) Tfh cells (E), GC Tfh cells (F), and germinal center B cells (G) were analyzed 12 days p.i., as for day 8 and described in (A)–(C). Data are representative of two
independent experiments for day 8 and day 12; n = 4 per group.
(H–K) B6mice were infected with VACV and treated with anti-ICOSL (aICOSL) or isotype control mAb at day 3, 5, and 7 as schematically shown in Figure S4E. Tfh
cells (H), GC Tfh cells (I), Bcl6 expression (J), and GC B cells (K) were analyzed 8 days p.i. Abbreviations: C, isotype control mAb-treated mice; aICOSL, anti-
ICOSL-treated mice; N, naive uninfected mice. n = 5–6 per group.
Data are representative of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars are SEM. See also Figure S4.
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Tfh Cell Fate Determination Pathways(CD44hi; Figure S5E) were normal for Bcl6-shRNA-transduced
SM CD4+ T cells, CXCR5 was not expressed when Bcl6 was
suppressed (p = 0.001; Figure 5G). Collectively, our data define938 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.a molecular hierarchy in Tfh cell commitment initiated at T cell
priming, wherein ICOS signals to induce Bcl6, which subse-
quently induces high CXCR5 expression.
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Figure 5. ICOS/ Bcl6/ CXCR5
(A–E) Blimp1-expressing (Prdm1-RV+, GFP+) and nontransduced (GFP) SM CD4+ T cells were transferred into the same (A) or separate (B–E) B6 recipient mice.
(A) SM CD4+ T cells at day 4 after LCMV infection.
(B) WT SM versus Prdm1-RV+ SM CD4+ T cell expansion (percent of total CD4+ T cells).
(C and D) CXCR5 expression by Prdm1-RV+ SM and WT SM, day 4 p.i.
(C) Representative FACS plots showing WT (GFP–) and Prdm1-RV+ (GFP+). Gates identify CXCR5+Bcl6+ SM.
(D) Quantitation of CXCR5+ and CXCR5+Bcl6+ SM.
(E) CXCR5+ SM and Bcl6+CXCR5+ Tfh cell frequencies day 3 p.i.
(F and G) Bcl6 shRNA-RV+ (GFP+Ametrine+) and nontransduced (GFPAmetrine) SM CD4+ T cells were transferred into separate B6 recipient mice subse-
quently infected with LCMV.
(F) SM CD4+ T cell expansion, day 4 p.i. (percent of total CD4+ T cells).
(G) Representative FACS plots of CXCR5 and Bcl6 expression by WT SM and Bcl6 shRNA+ SM CD4+ T cells. Total SM cells are shown and gates identify
Bcl6+CXCR5+ SM.
Data are representative of three (A–E) and two (F–G) independent experiments; n = 4 per group per time point. **p < 0.01, ***p < 0.001. Error bars are SEM. See
also Figure S5.
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IL-2 Receptor versus ICOS Signals
Given the rapid in vivo differentiation of Bcl6+CXCR5+CD4+
T cells, we next examined when the earliest developmental
features of Tfh cells versus effector Th cells can be distinguished.
We previously reported that Bcl6 and Blimp1 are antagonistic
transcription factors differentially expressed in Tfh and effec-
tor Th cells, respectively (Johnston et al., 2009). By using aBlimp1-YFP reporter, we now show that this bifurcation is
dramatically polarized. Day 8 effector SM cells fall into two clear
populations: Blimp1+ effector Th cells and Blimp1CXCR5+ Tfh
cells (Figure 6A). The Blimp1 Tfh cells express more Bcl6 than
Blimp1+ effector Th cell counterparts (p = 9.03 107; Figure 6B).
This reinforces the concept that Blimp1 and Bcl6 serve as
a bimodal transcription factor switch in CD4+ T cell differentiation
(Fazilleau et al., 2009; Johnston et al., 2009).Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc. 939
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Figure 6. Rapid Bcl6 versus Blimp-1 Bifurcation of CD4+ T Cell Differentiation In Vivo
(A) Blimp1 and CXCR5 expression by Blimp1-YFP BAC tg SM CD4+ T cells was analyzed at 8 days p.i. in B6 recipient mice. Gates identify Blimp1+CXCR5
effector Th cells and Blimp1CXCR5+ Tfh cells.
(B) Left, Bcl6 expression in Blimp1+CXCR5 (gray filled) versus Blimp1CXCR5+ (black line) SM CD4+ T cells. Right, Bcl6 MFIs.
(C) Day 3 p.i., analysis of Blimp1, Bcl6, and CXCR5 expression by Blimp1-YFP BAC Tg SM CD4+ T cells in B6 recipients. Representative FACS plots of SM cells
from LCMV-infected (Day3) and uninfected (Naive) recipients are shown. CXCR5 and Bcl6 expression by Blimp1+ versus Blimp1 SM CD4+ T cells were
quantified. Ctrl, isotype control stain.
(D) MD4-mMT recipient mice of Blimp1-YFP BAC tg SM CD4+ T cells, day 3 p.i. Representative FACS plot of SM cells and CXCR5 quantitation.
(E–G) Blimp1-YFP SMCD4+ T cells were transferred into B6 recipients and analyzed for IL2Ra expression 3 days after LCMV infection. IL2Rahi versus IL2Ralo SM
CD4+ T cells are identified in costains with CXCR5 (E), Bcl6 (F), and Blimp1 (G).
Data in all panels are representative of three or more independent experiments; n = 3–4 per group. **p < 0.01, ***p < 0.001. Error bars are SEM.
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Tfh Cell Fate Determination PathwaysBlimp1 expression is commonly considered a late event in
effector T cell differentiation (Martins and Calame, 2008; Rutish-
auser et al., 2009). However, given that Bcl6+CD4+ T cells could
be identified at day 3 in vivo, we examined whether Blimp1+
effector CD4+ T cells might be also identified early in the immune
response. Indeed, already by day 3, antiviral CD4+ T cells segre-
gated into two distinct cell types: Blimp1+ or Blimp1, with
significant CXCR5 induction only on Blimp1 populations940 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.(p = 1.09 3 105; Figure 6C). Importantly, day 3 Blimp1+ and
Blimp1 populations (Blimp1 MFI difference, p = 8.1 3 105)
showedreciprocalBcl6expression (Bcl6MFIdifference,p=0.004;
Figure 6C). The early bifurcation in Blimp1+CXCR5lo/ effector Th
cell versus Bcl6+CXCR5hi Tfh cell differentiation occurred via DC
priming, as shown by the fact that it was able to occur in the
absence of cognate B cells (46% Blimp1+ and 53% Blimp1 SM
inB6; Figure6C; 46%Blimp1+and54%Blimp1SM inMD4-mMT;
Immunity
Tfh Cell Fate Determination PathwaysFigure 6D). Thus, DC priming instructs a bifurcation between
Blimp1- and Bcl6-expressing CD4+ T cells by day 3 in vivo.
Blimp1 can be induced by IL-2 (Malek and Castro, 2010;
Martins and Calame, 2008). Therefore we examined expression
of the high-affinity IL-2 receptor alpha subunit (IL2Ra, CD25) at
day 3 p.i. Two clear SM cell populations were distinguishable:
IL2RahiCXCR5lo and IL2RaloCXCR5hi (Figure 6E). Strikingly,
98% less IL2Ra was expressed on Bcl6+CD4+ T cells compared
to Bcl6loCD4+ T cells (p = 0.0002; Figure 6F). Conversely, Blimp1
was strictly expressed in the cells with high IL2Ra expression
(p = 0.00008; Figure 6G). In contrast to ICOS-mediated Bcl6
induction (Figure 3), these data demonstrate a competing
pathway, via which IL-2-mediated Blimp1 upregulation occurs
through IL2Ra signaling.
The dramatic segregation in CD4+ T cell differentiation
observed by day 3 led us to examine an even earlier in vivo
time point. Surprisingly, at 48 hr p.i., Tfh versus effector Th cell
differentiation was already distinguishable. First, we determined
that IL2Ra expression is not homogeneous at this time point (Fig-
ure 7A). Although a large percentage of antiviral CD4+ T cells
were IL2Rahi, a significant percentage was IL2Raint (p = 1.5 3
107; Figure 7A). Importantly, IL2Raint cells exhibited the highest
CXCR5 MFI (p = 4.9 3 106; Figure 7B) and, indeed, expressed
the highest amounts of Bcl6 (p = 0.00001; Figure 7C). The early
IL2RahiCXCR5lo versus IL2RaintCXCR5hi SM cell polarization
was also observed in the absence of cognate B cells (MD4-mMT,
p = 0.00004; Figure 7D). Again, the IL2Raint SM cells expressed
the highest amounts of Bcl6 (p = 0.0002; Figure 7E). Therefore,
early differential IL2Ra expression occurs during CD4+ T cell
priming by DCs and is associated with distinct differentiation
fates of the CD4+ T cells. Given that Bcl6 induction was already
identifiable by 48 hr in vivo and was segregated in the IL2Raint
SM population, we examined whether Blimp1 was expressed
at this very early time point. Indeed, at 48 hr p.i., strong Blimp1
expression was already occurring in 35% of antiviral CD4+
T cells (approximately half of the IL2Rahi cells; Figure 7F).
Notably, Blimp1 expression specifically occurred in the CD4+
T cells that expressed the highest amount of IL2Ra (p = 1.5 3
106 IL2Raint versus IL2RahiBlimp1; p = 2.7 3 1010 IL2Raint
versus IL2RaintBlimp1; Figure 7G), which is the opposite of
the Bcl6 expression pattern (p = 6.2 3 107 IL2Raint versus
IL2Rahi; Figure 7H). Virus-specific CD4+ T cells at this 48 hr
time point had predominantly undergone only two (40%) or three
(37%) cell divisions (Figure 7I). IL2RaintBcl6+ cells were equally
present in both the two and three cell division populations (Fig-
ure 7J). Collectively, our data indicate that differential ICOS
versus IL2Ra signaling within the first two cell divisions is a major
decision point directing Bcl6 or Blimp1 expression and Tfh
versus effector Th cell differentiation during T cell priming.
DISCUSSION
Accumulating evidence has determined that Bcl6 is a critical
determinant for the development and function of Tfh cells;
however, themechanisms bywhich Bcl6 is induced and Tfh cells
develop have remained mostly unclear. Here we have used
a variety of genetic and in vivo cellular approaches to show
that Bcl6 induction and Tfh cell differentiation is initiated
upon DC priming in vivo and requires ICOS. Notably,Bcl6+CXCR5+CD4+ T cells can be identified within the first two
cell divisions in vivo, with strong polarization between Bcl6-ex-
pressing and Blimp1-expressing Th cells by 3 days p.i. These
findings revise our understanding of both the mechanism and
kinetics of Tfh cell differentiation.
Previous studies have shown that Tfh cells are a distinguish-
able cell type in vivo required for germinal center development
and that the emergence of Tfh cells is fully dependent on Bcl6
expression (Crotty, 2011). Nevertheless, there has been little
consensus regarding the nature of Tfh cell differentiation, in
part resulting from lack of information about the earliest events
in Tfh cell differentiation in vivo. One commonly held model of
Tfh cell differentiation was that the Tfh cell program is a sec-
ondary program acquired later by some Th1, Th2, or Th17 cells,
and Tfh cells do not exist as an independent cell type. Our data
do not support that model. A detailed examination of the kinetics
of development of Tfh cells in vivo revealed that Bcl6 expression
occurs in a subset of CD4+ T cells within two cell divisions after
infection. These findings support models of Tfh cell differentia-
tion whereby Tfh cell development is not contingent on a CD4+
T cell first acquiring Th1, Th2, or Th17 cell characteristics.
Our findings also clarify the relationship between Tfh cells and
APCs, particularly B cells and dendritic cells. Previous studies
found that Tfh cells were largely dependent on B cells. We
confirmed that the presence of Tfh cells at time points later
than 1 week postinfection was dependent on B cells, specifically
cognate B cells. In addition, B cell interaction with Tfh cells is
required for maintenance of Bcl6 expression in Tfh cells. Never-
theless, Tfh cell differentiation initiates independently of B cells,
as evidenced by normal Bcl6 induction in B cell-deficient mice at
day 3 p.i. In parallel experiments, we reasoned that presence of
Bcl6+CD4+ T cells within two divisions in vivo implicated DCs as
the responsible APCs for the CD4+ T cells, given the rarity of
cognate B cells early. Indeed, DC immunization experiments re-
vealed that DC priming can induce Bcl6 and CXCR5 in CD4+
T cells. B cells become the primary APCs after approximately
day 3 to 4 p.i., probably because of the increased availability
of antigen-specific B cells as APCswhen they undergo extensive
clonal expansion, as well as the colocalization of the antigen-
specific B cells and Tfh cells. This APC shift is probably also
due to death of the majority of the antigen-presenting mature
DCs by 4 days after an acute viral infection or protein immuniza-
tion, limiting MHCII-presented antigen in the lymphoid tissue
predominantly to B cells after this time. B cells can influence
T cell responses in a variety of situations (Lund and Randall,
2010). This phenomenon of distinct stimulation requirements
for initiation of differentiation and then maintenance of differenti-
ation is a common feature of many developmental processes in
biology, including CD4+ T cell differentiation, as observed by the
instability of iTreg or Th17 cell differentiation in the absence of
cofactors or sustained signals. A distinct attribute of Tfh cell
differentiation is the requirement for two different APC types at
two stages of differentiation.
Each simple model of Tfh cell differentiation (cytokine
program, B cell-dependent program, and secondary program)
has had strengths and weaknesses. Our studies here now allow
for proposal of an integrated model of Tfh cell differentiation,
focused on the central role of Bcl6 in this process. We have
found that Bcl6 expression occurs early during DC priming,Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc. 941
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Figure 7. Tfh versus Effector Th Cells Are Distinguishable by the Second Cell Division, in Association with Differential Early IL-2Ra
Expression Levels
Early virus-specific Tfh versus effector Th cell differentiation was analyzed at 48 hr after acute LCMV infection.
(A) Representative FACS plots of SM CD4+ T cells from LCMV-infected (Day 2) and uninfected (Naive) mice. Gates identify IL2RahiCXCR5lo versus
IL2RaintCXCR5hi SM CD4+ T cells.
(B) CXCR5 expression by IL2Rahi (black) versus IL2Raint (red) SM CD4+ T cells. Isotype control shown by gray filled histogram.
(C) Bcl6 expression by IL2Rahi versus IL2Raint SM CD4+ T cells.
(D) Expression of IL2Ra and CXCR5 by SM CD4+ T cells in MD4-mMT recipients, day 2 p.i.
(E) Bcl6 expression by SM CD4+ T cells in MD4-mMT recipients, day 2 p.i.
(F) IL2Ra and Blimp1 expression by Blimp1-YFPSMCD4+ T cells in B6 recipients, day 2 p.i. Representative SMCD4+ T cell FACSplot and quantitation are shown.
(G) IL2Ra expression (MFI) by SM CD4+ T cell populations gated in (F).
(H) Bcl6 expression by SMCD4+ T cells in B6 recipients at day 2 p.i. Gates identify IL2Rahi versus IL2Raint SM CD4+ T cells. Bcl6 protein expression (MFI) by each
population was calculated.
(I and J) CFSE-labeled SMCD4+ T cells were transferred into B6 recipient mice subsequently infected with LCMV. Cell divisions and differentiation were analyzed
at day 2 p.i.
(I) Cell divisions. Gray filled histogram show SM CD4+ T cells in uninfected mice.
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Tfh Cell Fate Determination Pathwaysand Tfh cell maturation occurs quickly thereafter. The cytokine-
only model does not suffice, on the basis of the requirement for
ICOS signaling during DC priming for Bcl6 expression, as well as
the limited impact of IL6, IL21 double deficiency (Eto et al., 2011).
The B cell-dependence model does not suffice, on the basis of
the early Tfh cell differentiation in the absence of B cells. The
secondary program model fails on the basis of Bcl6 induction
and Tfh cell differentiation occurring immediately upon DC
priming. Nevertheless, aspects of each of these available
models were accurate, supported by quality data from multiple
published studies. Therefore, key attributes of each are incorpo-
rated into our integrated model based on their biological rele-
vance (Figure S6). The secondary program model is inaccurate,
but it is nevertheless true that Tfh cells may possess attributes of
Th1, Th2, or Th17 cells in some conditions. IL-4, IFN-g, and IL-17
can be important class switch factors produced by Tfh cells to
control B cell antibody isotypes. We interpret these findings
as evidence that Tfh cell differentiation that occurs at the time
of DC priming is done in the context of a cytokine milieu that,
depending on the conditions, can allow partial Th1 (or Th2 or
Th17) cell features that coexist with the Tfh cell program. This
may relate to the recently appreciated functional plasticity of
CD4+ T cells (Murphy and Stockinger, 2010).
ICOS is the only homolog of CD28 found in humans or mice.
ICOS has functions distinct from CD28 because of two unique
characteristics. Unlike CD28, ICOS is not expressed on resting
T cells and is rapidly upregulated after TCR stimulation (Hutloff
et al., 1999). Second, the signaling motifs in the cytoplasmic
tail of ICOS are distinct from those of CD28 (Yong et al., 2009).
The importance of ICOS for germinal centers and T cell-depen-
dent antibody responses was rapidly recognized with Icos/
mice (McAdam et al., 2001; Tafuri et al., 2001). Rare ICOS-defi-
cient humans have a severe loss of antibody responses and
memory B cells (Warnatz et al., 2006). In the absence of ICOS,
reduced Tfh cell numbers are observed in bothmice and humans
(Akiba et al., 2005; Bossaller et al., 2006; Grimbacher et al.,
2003). Conversely, overexpression of ICOS in mice resulting
from a loss-of-function mutation in Roquin (sanroque) causes
severe autoimmunity via unchecked germinal center develop-
ment and autoantibody production (Vinuesa et al., 2005). Sanro-
quemice have dramatic increases in Tfh cell numbers (Linterman
et al., 2009; Vinuesa et al., 2005). Although ICOS is clearly impor-
tant for germinal centers and Tfh cell development, it has been
unknown why ICOS is so central to this process. We reasoned
that ICOS may be required for initiation of Tfh cell differentiation
by induction of Bcl6 in CD4+ T cells during DC priming. Consis-
tent with that idea, a profound defect in early Tfh cell differentia-
tion was demonstrated in the absence of ICOS. Notably, Bcl6
expression was substantially reduced, indicating that ICOS is
required for Bcl6 upregulation and subsequent Bcl6 control of
the Tfh cell differentiation program. Not only is ICOS required
for Bcl6 induction for Tfh cells during DC priming, ICOS signals
are again required a second time for Tfh cell maintenance of
Bcl6, this time from B cells during T cell- B cell cognate interac-
tions. Relevant to our studies, CXCR5+CD4+ T cells were(J) Representative FACS plots are shown of SM CD4+ T cells that have underg
IL2RaintBcl6+ SM CD4+ T cells.
Data in all panels are representative of three or more independent experiments; n =reduced in mice with B cell-specific deletion of ICOSL (ICOSLfl/fl
CD19-Cre) (Nurieva et al., 2008). Our experiments indicate that
the mechanism by which ICOS initiates Tfh cell differentiation
during DC priming is through Bcl6 expression. We found that
Bcl6 controls the downstream expression of CXCR5 in CD4+
T cells, thereby establishing a molecular hierarchy of Tfh cell
differentiation from ICOS to Bcl6 to CXCR5. This is consistent
with evidence that miR17-92 can reduce CXCR5 expression in
B cells (Yu et al., 2009). ICOS signals can promote IL-21 produc-
tion (Bauquet et al., 2009; Hiramatsu et al., 2010), and IL-21 can
enhance Bcl6 mRNA expression (Nurieva et al., 2009). However,
several studies showed that Tfh cells develop in Il21/ or
Il21r/mice (Crotty, 2011). Nevertheless, IL-6 and IL-21 doubly
deficient mice do exhibit reduced Tfh cell frequencies and
reduced Bcl6 expression by Tfh cells, confirming that these cyto-
kines do contribute to Tfh cell differentiation (Eto et al., 2011).
Intracellular signals from ICOS to induce Bcl6 expression are
probably augmented by cytokines to control Tfh versus effector
Th cell differentiation.
An important function of Bcl6 is repression of Blimp1. Tfh cells
express Bcl6 and effector Th cells express Blimp1 (Fazilleau
et al., 2009; Johnston et al., 2009). Blimp1 is capable of blocking
Bcl6 expression and thereby extinguishing the Tfh cell differenti-
ation program (Johnston et al., 2009). Our observation of the
dramatic bimodal polarization of CD4+ T cells to almost exclusive
Blimp1+ effector Th and Bcl6+ Tfh cell types at the peak of the
CD4+ T cell response highlighted the stringency of the antago-
nism between these two transcription factors. Blimp1 is known
to be expressed late in effector CD8+ T cell differentiation and
is considered a late marker of T cell differentiation. Surprisingly,
polarized Bcl6 versus Blimp1 expression was found as early as
48 hr p.i., after only two cell divisions. We infer from these results
that Bcl6 and Blimp1 are important early orchestrators of CD4+
T cell differentiation, thereby driving antagonistic and self-rein-
forcing differentiation processes. Given our finding that ICOS
signaling instructs Bcl6 expression and Tfh cell differentiation,
the knowledge that an early bifurcation occurs between Tfh
and effector Th cell developments during priming led us to ask
what signaling molecule may instruct Blimp1 in association
with canonical effector Th cell differentiation. One molecule
known to affect Blimp1 expression is IL-2 (Malek and Castro,
2010). The high-affinity IL2Ra subunit is crucial for IL-2-mediated
signaling and is expressed after TCR activation. Our study shows
that Blimp1 is regulated by CD4+ T cells according to differential
IL2Ra expression during the priming phase of the immune
response. At 48 hr p.i., the virus-specific CD4+ T cell population
possessed marked heterogeneity in IL2Ra expression, covering
a 100- to 500-fold range of variation in expression. A large
proportion of CD4+ T cells highly expressed IL2Ra and had
already upregulated Blimp1 expression. In contrast, cells pos-
sessing more moderate amounts of IL2Ra expression (IL2Raint)
instead expressed Bcl6.
IL-2 can induce Blimp1 in both CD4+ T cells and CD8+ T cells
(Malek and Castro, 2010). Interestingly, terminal effector CD8+
T cells (short-lived effector cells, SLECs) express Blimp1 andone two (left) and three (right) cell divisions. Gates identify IL2RahiBcl6 and
3–4 per group. **p < 0.01, ***p < 0.001. Error bars are SEM. See also Figure S6.
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tishauser et al., 2009). The question of how CD8+ T cell memory
is generated has been a topic of intensive interest in cellular
immunology. Recently it was determined that differential IL2Ra
expression on virus-specific CD8+ T cells as early as 3.5 days
after LCMV infection was associated with two separate cell
fates. IL2RahiCD8+ T cells express Blimp1 more than their
IL2Raint counterparts and consequentially are biased to differen-
tiate into terminal effector CD8+ T cells (SLEC) (Kalia et al., 2010;
Pipkin et al., 2010). Notably, CD8+ T cells that are instead
IL2Raint are destined to become memory precursor CD8+ T cells
(MPEC), which express elevated Bcl6 (Rutishauser et al., 2009),
in contrast to the Blimp1 expression by terminal effector CD8+
T cells. Therefore, CD8+ T cells undergo a fate choice decision
process during priming, surprisingly analogous to the mecha-
nism of CD4+ T cell Tfh cell differentiation we demonstrate
here. These parallels indicate that mechanisms limiting early
IL2Ra expression on T cells may enhance both Tfh cell differen-
tiation and the development of T cell memory.
Our study illuminates the involvement of ICOS versus IL2Ra
signals during priming for induction of Bcl6 expression and Tfh
cell differentiation and highlights the importance of further exam-
ination of the intersections and interplay between these antago-
nizing pathways for determining T cell fates. How are these two
upstream pathways regulated? ICOS-mediated signals for Tfh
cells require the phosphoinositide 3-kinase (PI3K) pathway
(Gigoux et al., 2009). Unlike CD28, ICOS fails to bind both
Grb2 and Gads and therefore does not induce IL-2 production
(Harada et al., 2003; Watanabe et al., 2006). It is plausible that
higher TCR affinity results in prolonged T cell-DC interactions
during the extended periods of CD4+ T cell-DC interaction in
the first 24 hr of priming in vivo (Celli et al., 2007; Mempel
et al., 2004). Higher TCR affinity is associated with a preference
for Tfh cell differentiation over effector Th cell differentiation
(Fazilleau et al., 2009). This maywell be due to higher TCR affinity
causing extended T cell-DC interactions, resulting in prolonged
ICOS-ICOSL exposure at the time of DC priming, with CD4+
T cell integration of total ICOS signal strength over the duration
of the APC interaction resulting in initiation of Tfh cell differentia-
tion. We hypothesize that repeated but less prolonged early
exposure of CD4+ T cells to antigen preferentially induces
IL2Ra expression. Each of these processes can be an amplifying
and self-reinforcing loop that would be capable of leading to
rapidly polarized Bcl6-expressing Tfh cells and Blimp1-express-
ing effector Th cells. It is appealing to consider that a comparable
ICOS signaling process could be occurring during T cell-B cell
interactions. The higher amount of ICOS expression on Tfh cells
combined with the duration of the T cell-B cell interaction deter-
mines the overall amount of ICOS signaling received by the Tfh
cells. The duration of T cell-B cell interaction is dependent on
the magnitude of SAP-dependent SLAM family receptor adhe-
sion. Such an idea is consistent with the requirement for SAP
to obtain GC Tfh cells and germinal centers. This is in keeping
with the concept that Tfh cell differentiation is amultistage, multi-
component process (Crotty, 2011).
Collectively, our findings provide mechanistic insights for
signaling pathways in regulation of two antagonizing transcrip-
tion factors that balance Tfh versus effector Th cell differentia-
tion. Given that most successful vaccines are dependent on944 Immunity 34, 932–946, June 24, 2011 ª2011 Elsevier Inc.CD4+ T cell provision of help to B cells to produce protective anti-
bodies and B cell memory, further understanding of Tfh versus
effector Th cells fate determination may be useful in rational
vaccine design.
EXPERIMENTAL PROCEDURES
Mice and Viral Infections
Mice were either purchased from the Jackson Laboratory or obtained from in-
house breeders (details in Supplemental Information). LCMV Armstrong and
VACVWR (Western Reserve strain) stocks were prepared and quantified as
previously described (McCausland et al., 2007; Sette et al., 2008). All animal
experiments were conducted in accordance with approved animal protocols
at LIAI.
Retrovirus Production and Cell Transfers
Prdm1 (Blimp1)-expressing retroviral vector (pMIG-GFP) was reported previ-
ously (Johnston et al., 2009). Bcl6 shRNA sequences were cloned into
pLMP-GFP (Open Biosystem) and a custom pLMP-Ametrine, with additional
modifications. Virions were produced from the Plat-E cell line as previously
described (Johnston et al., 2009) with some modifications. VSV-g-expressing
plasmid (pHDM-VSV-G) was cotransfected for each RV production for
increased virion stability. Culture supernatants were obtained 2 days after
transfections, filtered through 0.45 mm syringe filters, and ultracentrifuged at
24,000 rpm for 90 min. VSV-g-expressing chimeric retroviral stocks were
saved at 80C until use.
Naive or retrovirally transduced (details in Supplemental Information) SM
CD4+ T cells were transferred into recipient mice by intravenous injections
via the retro-orbital sinus. Cell transfer numbers for each time point were as
follows: 1 3 106, 4–5 3 105, 2 3 105, and 5 3 103 SM CD4+ T cells for day
2, 3, 4, and 8 (or 7) experiments, respectively.
Anti-ICOSL Treatments
Anti-ICOSL (rat IgG2a, clone HK5.3) and isotype control (rat IgG2a) mAbswere
purchased from BioXcell. C57BL/6 mice were given 100 mg of anti-ICOSL or
isotype control mAb via both i.p. and retro-orbitally 3 days after VACVWR
infection. Subsequent doses of 100 mg of mAbs were injected retro-orbitally
at 5 and 7 days after infection.
Flow Cytometry
Single-cell suspensions were obtained by a gentle mechanical disruption of
spleens. After ACK lysis, cell suspensions were surface stained in FACS buffer
(PBS + 0.5% BSA) with monoclonal antibodies: SLAM (CD150, Biolegend);
CD4, CD8, Fas, GL7 (BD Biosciences); CD44, CD45.1/2, IL2Ra (CD25),
CD62L, CD69, PD-1 (J43), ICOS, B220 (eBioscience); and PNA (Vector Labs).
CXCR5 stains and intracellular Bcl6 stains are described in Supplemental
Information. All FACS samples were washed twice with FACS buffer, acquired
with an LSRII (BD Biosciences), and then analyzed with FlowJo (Tree Star).
Statistics
Statistical analyses were done with Prism 5.0 (GraphPad). p values were cal-
culated with two-tailed unpaired Student’s t tests with a 95% confidence
interval. Error bars on bar graphs depict the standard error of mean (SEM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.
immuni.2011.03.023.
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